Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

ENDRA Life Sciences (NDRA) Long-Term Debt Repayments (2016 - 2024)

ENDRA Life Sciences has reported Long-Term Debt Repayments over the past 1 years, most recently at -$132000.0 for Q4 2016.

Quarterly Long-Term Debt Repayments changed N/A to -$132000.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was -$132000.0 through Sep 2018, changed N/A year-over-year, with the annual reading at $28484.0 for FY2024, N/A changed from the prior year.
Long-Term Debt Repayments was -$132000.0 for Q4 2016 at ENDRA Life Sciences.
Over five years, Long-Term Debt Repayments peaked at -$132000.0 in Q4 2016 and troughed at -$132000.0 in Q4 2016.